Feb 22, 2023· Comment from Association For Accessible Medicines (AAM)· FDA-2014-D-1167-0026
AAM comment letter (for the Dec 2021) Controlled Correspondence Related to Generic Drug Development; Guidance for Industry; Draft Guidance
FDANonrulemakingFDA-2014-D-1167
Controlled Correspondence Related to Generic Drug Development
RIN
—
Last modified
Mar 18, 2024
Comment window
closed 1253d ago
Association for Accessible Medicines filings
3
Activity
Association for Accessible Medicines filed 3 comments on this docket between Jan 5, 2018 and Feb 22, 2023. 0 other organizations filed here. The comment window closed 1253d ago.
What Association for Accessible Medicines filed (3)
Mar 8, 2021· Comment from The Association for Accessible Medicines (AAM)· FDA-2014-D-1167-0023
Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding docket No. FDA-2014-D-1167: Controlled Correspondence Related to Generic Drug Development.
Jan 5, 2018· Comment from Association for Accessible Medicines (AAM)· FDA-2014-D-1167-0019
Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding Docket FDA-2014-D-1167: Draft Guidance for Industry on Controlled Correspondence Related to Generic Drug Development.
Abstract
Announcement of Office of Management and Budget Approval Guidance for Industry
View on regulations.gov →Co-filers (0)
See everyone who commented →- Association for Accessible MedicinesTHIS ORG3 filings · confidence 97%